BridgeBio Oncology Therapeutics Inc. (BBOT) vs Eupraxia Pharmaceuticals Inc. (EPRX)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Eupraxia Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
EPRX
Eupraxia Pharmaceuticals Inc.
$7.74HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BBOT vs EPRX
growth of $100 · dividends reinvested · last 2yBBOT -64.8% (-40.7%/yr)EPRX +162.7% (+62.1%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
BBOT EPRX
BBOT vs EPRX: by the numbers
- •BBOT is the larger company ($280M vs $259M market cap).
Metrics side by side
Valuation
| Metric | BBOT | EPRX |
|---|---|---|
| P/B ratio | 0.87 | 2.55 |
Profitability
| Metric | BBOT | EPRX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -56.36% | -38.33% |
| ROIC | -61.10% | -43.56% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROEEupraxia Pharmaceuticals ROEBridgeBio Oncology Therapeutics operating marginEupraxia Pharmaceuticals operating marginBridgeBio Oncology Therapeutics revenue growthEupraxia Pharmaceuticals revenue growthBridgeBio Oncology Therapeutics free cash flowEupraxia Pharmaceuticals free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.